

NOTE: This disposition is nonprecedential.

**United States Court of Appeals  
for the Federal Circuit**

---

**ACORDA THERAPEUTICS, INC.,**  
*Plaintiff-Appellant*

**ALKERMES PHARMA IRELAND LIMITED,**  
*Plaintiff-Appellee*

v.

**ROXANE LABORATORIES, INC., MYLAN  
PHARMACEUTICALS INC., TEVA  
PHARMACEUTICALS USA, INC.,**  
*Defendants-Cross-Appellants*

---

2017-2078, 2017-2134

---

Appeals from the United States District Court for the District of Delaware in Nos. 1:14-cv-00882-LPS, 1:14-cv-00922-LPS, 1:14-cv-00935-LPS, 1:14-cv-00941-LPS, Chief Judge Leonard P. Stark.

---

**ON PETITION FOR REHEARING EN BANC**

---

Before PROST, *Chief Judge*, NEWMAN, DYK, MOORE,  
O'MALLEY, REYNA, WALLACH, TARANTO, CHEN, HUGHES,  
and STOLL, *Circuit Judges*.

2 ACORDA THERAPEUTICS, INC. v. ROXANE LABORATORIES, INC.

PER CURIAM.

**O R D E R**

Appellant Acorda Therapeutics, Inc. filed a petition for rehearing en banc. A response to the petition was invited by the court and filed by Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. The petition was first referred as a petition for rehearing to the panel that heard the appeal, and thereafter the petition for rehearing en banc was referred to the circuit judges who are in regular active service.

Upon consideration thereof,

IT IS ORDERED THAT:

The petition for panel rehearing is denied.

The petition for rehearing en banc is denied.

The mandate of the court will issue on January 11, 2019.

FOR THE COURT

January 4, 2019  
Date

/s/ Peter R. Marksteiner  
Peter R. Marksteiner  
Clerk of Court